Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs TransMedics Group Inc — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $34.4 (market cap $1.96B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and TransMedics Group Inc for 24 Days on average.
| SOXS | TMDX | |
|---|---|---|
Market Cap | $1.96B | $2.74B |
Volume | 113,512,541 | 949,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $988.00 | $150.42 |
52-Week Low | $29.62 | $61.99 |
Typical Hold Time | 11 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $34.53, up 12.68% with a bearish technical signal. The fund provides inverse leveraged exposure to semiconductor stocks, making it highly volatile and suitable for short-term tactical trades rather than long-term investment. Recent performance reflects semiconductor sector weakness, with technical indicators showing mixed signals but overall bearish momentum.
The outlook remains challenging as SOXS faces structural headwinds from persistent AI hardware demand and semiconductor industry strength. Investment opportunities exist for tactical bearish bets during sector pullbacks, but risks include high volatility, decay from daily rebalancing, and potential for rapid losses if semiconductor stocks rebound. The fund is best suited for experienced traders with short-term horizons.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
